NEW YORK (GenomeWeb News) – Genetic Technologies today said that New York has issued a Clinical Laboratory Permit to the firm, allowing GTG to offer its BREVAGen test to residents of the state.

The permit completes the out-of-state licensures needed, and GTG can offer the breast cancer test to all 50 states in the US. GTG received CLIA certification of compliance for its Australian lab in February 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.